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Protein aggregation is associated with age-related
neurodegenerative disorders, such as Alzheimer’s
and polyglutamine diseases. As a causal relationship
between protein aggregation and neurodegeneration
remains elusive, understanding the cellular mecha-
nisms regulatingproteinaggregationwill helpdevelop
future treatments. To identify such mechanisms, we
conducted a forward genetic screen in a C. elegans
model of polyglutamine aggregation and identified
the protein MOAG-2/LIR-3 as a driver of protein ag-
gregation. In the absence of polyglutamine, MOAG-
2/LIR-3 regulates the RNA polymerase III-associated
transcription of small non-coding RNAs. This regula-
tion is lost in the presence of polyglutamine, which
mislocalizes MOAG-2/LIR-3 from the nucleus to the
cytosol. We then show biochemically that MOAG-2/
LIR-3 can also catalyze the aggregation of polyglut-
amine-expanded huntingtin. These results suggest
that polyglutamine can induce an aggregation-pro-
moting activity of MOAG-2/LIR-3 in the cytosol. The
concept that certain aggregation-prone proteins can
convert other endogenous proteins into drivers of ag-
gregation and toxicity adds to the understanding of
how cellular homeostasis can be deteriorated in pro-
tein misfolding diseases.
INTRODUCTION
Neurodegenerative disorders such as Alzheimer’s, Parkinson’s,
and Huntington’s diseases represent a major health problem
and demandabetter understanding of themolecularmechanisms
of pathogenesis in order to develop disease-modifying treat-
ments. The hallmark of many neurodegenerative disorders is the1096 Molecular Cell 65, 1096–1108, March 16, 2017 ª 2017 The Auth
This is an open access article under the CC BY-NC-ND license (http://presence of protein aggregates in different brain areas of affected
patients (Soto, 2003). These insoluble macromolecular structures
are enriched in aggregation-prone proteins that—by exposing
certain regions of their amino acid sequences—associate in an
aberrant manner with other proteins, thereby hampering normal
cellular function (Eisenberg and Jucker, 2012; Olzscha et al.,
2011; also reviewed in Chiti and Dobson, 2009; Sin and Nollen,
2015). It is not yet clear, however, whether these protein aggre-
gates are actually a cause or a consequence of the disease. The
current view is that the soluble precursors of these aggregates—
in particular some oligomeric forms—are the main cytotoxic spe-
cies, and that at least in some cases the aggregation process
can represent a protective measure to sequester these smaller
harmful species (Arrasate et al., 2004; Bolognesi et al., 2010;
Kayed et al., 2003; Miller et al., 2011).
These observations focus the attention on the cellular factors
that can drive protein aggregation, which are currently poorly
understood. In some cases, direct aggregation-promoting fac-
tors have been identified, both in humans and in animal
models, and include SH3GL3 (Davranche et al., 2011; Sittler
et al., 1998), MOAG-4/SERF (Falsone et al., 2012; van Ham
et al., 2010), and UNC-30 (Garcia et al., 2007). More studies,
however, are needed to acquire a more comprehensive under-
standing of this phenomenon.
In this context, the roundworm C. elegans is a much-used an-
imal model for neurodegenerative diseases and is proving very
useful in providing a basic understanding of protein aggregation.
If we can use this model organism to identify genetic modifiers of
protein aggregation, then we can also obtain insight into the
cellular pathways that are dysregulated in the pathogenesis of
human protein misfolding diseases and target them for pharma-
cological intervention. Indeed, a wide variety of genetic screens
have already been performed in C. elegans to find genes that
regulate protein aggregation and its associated toxicity (Hama-
michi et al., 2008; Kuwahara et al., 2008; Lejeune et al., 2012;
Nollen et al., 2004; Silva et al., 2011; van der Goot et al., 2012;
van Ham et al., 2010). The aim of the current study is to identify
genes that drive protein aggregation, to discover the function ofor(s). Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
such genes, and to understand how they are related to protein
aggregation. We identified MOAG-2/LIR-3 as a modifier of
aggregation, since this protein in the presence of polyglutamine
shifts its role from a transcriptional regulator of small non-
coding RNAs (ncRNAs) to an aggregation and toxicity promoting
factor.
RESULTS
Inactivation of MOAG-2/LIR-3 Reduces Polyglutamine
Aggregation
To identify genes whose products are capable of driving pro-
tein aggregation, we performed a forward genetic screen in a
C. elegans model in which the body-wall muscle cells express
a transgene consisting of an aggregation-prone polyglutamine
stretch of 40 residues fused to YFP (Q40-YFP) (van Ham et al.,
2010). We screened for mutants with reduced polyglutamine
aggregation, andwe named the resulting genes ‘‘modifiers of ag-
gregation’’ (moag) (van Ham et al., 2010). At the fourth larval
stage (L4), moag-2(pk2183) (hereafter designated as moag-2/
lir-3(pk2183)) showed a reduction of about 50% in the number
of aggregates relative to the wild-type Q40 worms (Figures 1A,
1B, and S1A). SNP mapping and genome sequencing allowed
us to fine-map the causal mutation and revealed six genes as pu-
tative candidates for moag-2 (Figure S1B). For one of these,
which mapped to lir-3 (lin-26 related; sequence: F37H8.1;
GenBank: NM_063994), the causative mutation was in the start
codon, replacing the first methionine with an isoleucine (Met1Ile)
(Figures 1C and S1B).
The lir-3 gene encodes a LIN-26-like zinc-finger protein of un-
known function (http://www.wormbase.org/, June 2016). It is
predicted to have two zinc-finger domains of the C2H2 type (res-
idues 191–214 and 224–247) at the carboxyl terminus and a
nuclear localization signal spanning amino acid residues 132–
141 (http://nls-mapper.iab.keio.ac.jp/, June 2016) (Figure S1C).
LIR-3 shares two non-canonical C2H2 zinc-finger motifs with
three other C. elegans proteins: LIN-26 (31%–35% similarity),
LIR-1 (20%–31%similarity), and LIR-2 (25%similarity) (Dufourcq
et al., 1999).
To assess whether moag-2 was lir-3, we used an lir-3(tm813)
deletion mutant (hereafter designated as ‘‘moag-2/lir-3(tm813)’’)
and crossed it with the polyglutamine (Q40) worm model. This
strain has a 795 bp deletion spanning residues 276–1,070 of
the F37H8.1 sequence that also causes a premature stop codon
(Figures 1C and S1C). This partial deletion of lir-3 caused a 35%
reduction of aggregates relative to the numbers seen in wild-type
worms (Figure 1D). Worms heterozygous for lir-3 deletion allele
had aggregate numbers similar to those seen in the wild-type,
suggesting that the reduction of aggregation was recessive and
due to the loss of function of lir-3 (Figure 1D). We next asked
whether overexpression of lir-3 could restore the aggregation
phenotype. To this end, we injected worms with a rescue frag-
ment, consisting of full-length lir-3, including a 1.5 kb sequence
upstream of the start codon to include its endogenous promoter
as well as 330 bp downstream to include the 30 UTR (Figure 1C).
Expression of the lir-3 rescue fragment in Q40; lir-3(tm813)
worms was able to restore the aggregation phenotype by 2-fold
(p < 0.001), confirming lir-3 as a gene responsible for driving ag-gregation in the polyglutamine model (Figures 1E and S1D).
Taken together, these results demonstrate that lir-3 is moag-2.
A specific property of protein aggregates in the brains of
neurodegenerative disease patients that is also captured by
the C. elegans polyglutamine model used here is that they are
typically insoluble in strong detergents such as sodium dodecyl
sulfate (SDS) (Lee et al., 1999; Shankar et al., 2008; Yanamandra
et al., 2015). To establish whether MOAG-2/LIR-3 promoted
aggregation of SDS-insoluble polyglutamine aggregates, we
performed a filter retardation assay on lysates of wild-type and
moag-2/lir-3 mutant polyglutamine worms (Scherzinger et al.,
1997; Wanker et al., 1999). This assay enables the detection of
SDS-insoluble protein aggregates, while soluble species are
not captured. Both Q40;moag-2/lir-3(pk2183) and Q40;moag-
2/lir-3(tm813) mutants had fewer SDS-insoluble aggregates
than their corresponding Q40 controls (Figure 1F). The reduction
of SDS-insoluble aggregates was more pronounced in the
point mutant (43%; p = 0.05) than in the deletion mutant (26%;
p = 0.18) (Figure S1E). Mutation or partial deletion of moag-2/
lir-3 did not cause a discernible reduction in the transcription
or the protein expression level of Q40-YFP, indicating that
moag-2/lir-3 does not reduce aggregation by reducing expres-
sion levels of theQ40-YFP protein (Figures 1F and 1G). Together,
these results indicate that moag-2/lir-3 drives the formation of
SDS-insoluble polyglutamine aggregates.
MOAG-2/LIR-3 Is a C2H2-Domain Protein Associated
with RNA Polymerase III Promoters
Having established that mutation of moag-2/lir-3 reduces poly-
glutamine aggregation, we next determined the endogenous
function of the corresponding protein. C2H2 zinc-finger domains
are predominantly associated with DNA-binding transcription
factors but may also have other functions such asmediating pro-
tein-protein interactions or binding to RNA (Brown, 2005; Hall,
2005; Krishna et al., 2003). Bioinformatics analysis combined
with manual curation predictedMOAG-2/LIR-3 to be a transcrip-
tion factor (Reece-Hoyes et al., 2005, 2007). To explore this
possibility, we determined the subcellular localization of FLAG-
tagged MOAG-2/LIR-3 protein in wild-type N2 worms. Indirect
immunofluorescence using an anti-FLAG antibody revealed
that MOAG/LIR-3 is localized in the nucleus (Figures 2A
and S2A).
Next, we performed chromatin immunoprecipitation followed
by deep sequencing (ChIP-seq) in L4-staged worms that ex-
pressed an integrated construct of lir-3 fused to FLAG and
GFP (Sarov et al., 2012; Zhong et al., 2010). This analysis yielded
a total of 678 unique MOAG-2/LIR-3 binding sites, 404 of which
overlapped with 813C. elegans genes. Further analyses of these
genes revealed that MOAG-2/LIR-3 binding was enriched in the
transcription start sites (TSSs) of tRNA genes (35.7%, p < 0.001),
small nucleolar RNA (snoRNA) genes (6.3%, p < 0.001), rRNA
genes (2.5%, p < 0.001), and small nuclear RNA (snRNA) genes
(2.2%, p < 0.002) (Figures 2B and S2B). While MOAG-2/LIR-3
was also found in the vicinity of protein-coding and other ncRNA
genes, this binding was not significantly enriched (Figures 2B,
2C, and S2B).
We then asked whether the binding sites were enriched in
any consensus sequence motif that could be recognized byMolecular Cell 65, 1096–1108, March 16, 2017 1097
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Figure 1. Identification of moag-2/lir-3 as an Aggregation-Promoting Factor
(A) Number of aggregates in Q40 worms and Q40;moag-2(pk2183) worms.
(B) Representative images of Q40 worms and Q40;moag-2(pk2183) worms. Scale bar, 75 mm. See also Figure S1A.
(C) Chromosomal location of lir-3 (F37H8.1, chromosome II, reverse strand of assembly; http://www.wormbase.org, WS248), showing the point mutation in the
start codon (red arrow), the partial deletion (red bar), and the rescue fragment (green). See also Figures S1B and S1C.
(D) Number of aggregates in Q40 worms with either wild-type alleles, or heterozygous (het) or homozygous (tm813) deletion for the lir-3(tm813) allele.
(E) Number of aggregates in Q40 worms and Q40;lir-3(tm813) worms, with and without transgenic overexpression of an injected lir-3 rescue fragment, including
its endogenous promoter. See also Figure S1D.
(F) Filter retardation assay with 5-fold serial dilutions of crude protein extract fromQ40 worms and Q40;moag-2/lir-3mutant worms. The results shown are from a
representative experiment of three biological replicates. Q40-YFP and a-tubulin expression were included as controls. See also Figure S1E.
(G) Q40-YFP transcript expression detected by RNA sequencing in L4-stage worms and protein expression detected in urea-treated L4-stage worms and day 1
adult worms.
In all panels, aggregate counting, representative images, and filter retardation assay were performed at the L4 stage and the average of three biological replicates
is represented. Data are represented as mean ± SEM and significance was calculated using a one-tailed unpaired Student’s t test. **p < 0.01; ***p < 0.001.MOAG-2/LIR-3. Of the 678 binding sites initially identified in our
ChIP-seq data, more than half of the sites contained Box A and
Box B sequencemotifs, 301 of which contained both motifs (Fig-
ures 2D and 2E). Box A andBox B constitute the canonical type 2
promoter site recognized by the RNA polymerase (Pol) III com-
plex (Ikegami and Lieb, 2013; Schramm and Hernandez, 2002).
Pol III is responsible for the transcription of structural or catalytic
snRNAs, of tRNAs, and of snoRNAs, which mediate chemical1098 Molecular Cell 65, 1096–1108, March 16, 2017modifications of other RNA molecules (Bratkovic and Rogelj,
2014; Guthrie and Patterson, 1988; Schramm and Hernandez,
2002; White, 2011). These findings led us to hypothesize that
MOAG-2/LIR-3 may bind to the same target promoters as
Pol III. Binding in the proximity of non-coding genes has been
shown on occasion for several C. elegans transcription factors,
including PHA-4, PQM-1, and GEI-11 (Niu et al., 2011). These
observations prompted us to ask whether the association
Figure 2. MOAG-2/LIR-3 Preferentially Binds to Promoters of Small ncRNAs
(A) Subcellular localization of MOAG-2/LIR-3 in wild-type N2 worms. Scale bar, 50 mm. Arrowheads point at nuclei; asterisk is non-specific staining. See also
Figure S2A.
(B) Enrichment of binding of MOAG-2/LIR-3 to different gene biotypes (1 kb upstream/downstream of TSS) relative to genes distributed genome-wide. See also
Figure S2B.
(legend continued on next page)
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between MOAG-2/LIR-3 and the Pol III complex resembled
the binding of these transcription factors to the promoters
of non-coding genes. To answer this question, we collected
publicly available ChIP-seq data for known C. elegans transcrip-
tion factors (http://www.modencode.org, September 2014) and
analyzed binding to the promoters of protein-coding genes,
snoRNA genes, and tRNA genes (Figure 2F). While there is little
association between MOAG-2/LIR-3 and the promoters of pro-
tein-coding genes, the MOAG-2/LIR-3 binding profile is very
similar to that of a group of clustered factors that contain repre-
sentative components of the Pol III complex. These factors
include Pol III, TATA binding protein (TBP-1), two subunits of
the transcription factor for Pol III C (TFC-1 and TFC-4), and the
nuclear pore proteins NPP-3 and NPP-13, which have recently
been shown to associate with the Pol III complex to regulate
tRNA and snoRNA splicing (Ikegami and Lieb, 2013). In contrast
to the majority of the other transcription factors, the binding of
these factors is very abundant in the promoters of snoRNAs
and of tRNAs (Figure 2F). Therefore, the binding of MOAG-2/
LIR-3 to the promoters of small ncRNA genes suggests that
MOAG-2/LIR-3 is associated with Pol III transcription.
MOAG-2/LIR-3 Is aPositive Regulator of Pol III-Mediated
Transcription of Small ncRNAs
Because we found MOAG-2/LIR-3 to bind to the promoters of
small ncRNA genes, we next asked what consequences this
binding had for the transcription of Pol III downstream targets.
We therefore used transcriptome profiling to compare RNA
expression in wild-type worms with that in moag-2/lir-3 mutant
worms. In line with the absence of MOAG-2/LIR-3 at RNA
Pol II promoter sites, we did not find any protein-coding genes
that were differentially expressed between the mutants and
wild-type N2 worms, thereby excluding MOAG-2/LIR-3 as a
transcriptional regulator of protein-coding genes (Figures 3A
and S3A). Mutations in moag-2/lir-3, however, did result in the
downregulation of snRNAs (p < 0.001), snoRNAs (p < 0.001),
and tRNAs (p < 0.001) in both mutants, demonstrating that
MOAG-2/LIR-3 regulates Pol III-mediated transcription of these
small ncRNAs (Figures 3A and S3A).
We next asked where in the TSS region MOAG-2/LIR-3 was
positioned relative to the Pol III complex. To this end, we
compared the positions of the ChIP-seq signals of MOAG-2/
LIR-3 with those of the different components of the Pol III com-
plex. For both the tRNA and snoRNA genes, all factors localized
to the Box A- and Box B-containing promoter region, consistent
with previous reports (Figures 3B, 3C, and S3B) (Ikegami and
Lieb, 2013). MOAG-2/LIR-3 was also positioned at these same
sites (Figures 3B and 3C).
Next, we tested whether MOAG-2/LIR-3 interacts physically
with the Pol III complex by means of immunoprecipitation exper-
iments. We found that FLAG-tagged MOAG-2/LIR-3 protein co-
immunoprecipitated with Pol III, but not detectably with Pol II,(C) MOAG-2/LIR-3 binding sites within 1,000 and +1,000 bp of TSS for protein
(D) Enriched consensus DNA motifs for MOAG-2/LIR-3 with p value.
(E) Number of MOAG-2/LIR-3 binding sites containing Box A and Box B.
(F) Heatmap showing the binding of different transcription factors to C. elegan
clustering was generated using the average linkage cluster method with a binary
1100 Molecular Cell 65, 1096–1108, March 16, 2017confirming that MOAG-2/LIR-3 cooperates with the Pol III
machinery to drive transcription of small ncRNAs (Figures 3D
and S3C). The fact that MOAG-2/LIR-3 did not detectably co-
immunoprecipitate with Pol II further supports the notion that
MOAG-2/LIR-3 is not directly involved in the transcription of pro-
tein-coding genes (Figure 3D).
Together these results indicate that MOAG-2/LIR-3 functions
as a positive regulator of the Pol III-mediated transcription of
small ncRNAs in C. elegans.
Regulation of Protein Aggregation by MOAG-2/LIR-3 Is
Independent of Its Role as a Transcriptional Regulator
Next, we asked whether MOAG-2/LIR-3 regulated protein ag-
gregation via the Pol III-mediated transcription of small ncRNAs.
We therefore used RNAi to knock down, one by one, the in-
dividual components of the Pol III complex in both wild-type
worms and moag-2/lir-3(pk2183) mutants. To confirm RNAi
knockdown, we also looked for RNAi-associated phenotypes
other than aggregation. If Pol III-mediated transcription were
involved in promoting protein aggregation, this would result
in a reduction in the amount of aggregates in the wild-type
Q40 worms, but not in the moag-2/lir-3 mutants. However,
knockdown of Pol III, TBP-1, or TFC-1 did not alter aggre-
gation in the Q40 worms or in the Q40;moag-2/lir-3 mutant
strains, indicating that in the absence of moag-2/lir-3 it is
not the resulting lack of Pol III-mediated transcription that is
responsible for the reduction in aggregation (Figures 4A, S4A,
and S4B).
The nuclear pore protein npp-13 has been shown to interact
with the Pol III complex and regulate the processing of small
ncRNAs (Ikegami and Lieb, 2013). The aggregation phenotype
was not altered by knockdown of npp-13 or of tRNA-processing
enzymes, indicating that neither small RNA processing nor the
availability of mature tRNAs is involved in reducing aggregation
(Figures 4A, 4B, and S4A–S4C). These results indicate that the
regulation of protein aggregation by MOAG-2/LIR-3 is separate
from its involvement in RNA transcription together with the
Pol III complex.
Polyglutamine Suppresses Transcription of Small
ncRNAs
We next asked why the involvement of MOAG-2/LIR-3 in driving
protein aggregation is independent of its role as a transcriptional
regulator. We therefore first compared the RNA expression pro-
files of wild-type Q40 worms with those of moag-2/lir-3 mutant
Q40 worms. In contrast to wild-type N2 worms, there was no
longer a reduction in the relative expression levels of the small
ncRNAs in the presence of polyglutamine (Figures 4C and
S4D). When we then measured the absolute levels of all RNAs,
we found that in contrast to the protein-coding RNAs, pseudo-
genes, and other ncRNAs, the expression of snRNAs, snoRNAs,
and tRNAs was already strongly reduced in wild-type Q40-coding, ncRNA, tRNA, and snoRNA genes.
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Figure 3. MOAG-2/LIR-3 Regulates Transcription of Small ncRNAs
(A) Boxplot showing the relative expression of different gene biotypes in moag-2/lir-3(pk2183) worms relative to the wild-type N2 background. TPM, tags per
kilobasemillion; Coding, protein-coding genes; ncRNA, non-coding RNA; Pseudo, pseudogenes; snRNA, small nuclear RNA; snlRNA, snRNA-like RNA; snoRNA,
small nucleolar RNA; tRNA, transfer RNA. The average of three biological replicates is represented and significance was calculated using a two-tailed unpaired
Student’s t test. ***p < 0.001. See also Figure S3A.
(B) Positions of ChIP-seq signal maxima relative to TSS (right y axis) with maximum normalized read count (left y axis) for the 51 snoRNA genes and the 290 tRNA
genes picked in this study. Bottom box represents the motif position of Box A and Box B relative to snoRNA and tRNA genes. See also Figures S3B and S3C.
(C) Diagram showing the positions of the Pol III factors and that of MOAG-2/LIR-3 as estimated from the data presented in (B).
(D) Co-immunoprecipitation of FLAG-tagged MOAG-2/LIR-3 protein by a-Pol II and a-Pol III protein antibodies. IP, immunoprecipitation; WT, wild-type; OE,
MOAG-2/LIR-3 overexpression.
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Figure 4. Polyglutamine Reduces the Tran-
scription of Small ncRNAs
(A) Number of aggregates measured in Q40 and
Q40;moag-2/lir-3(pk2183) worms after RNAi knock-
down of individual components of the Pol III com-
plex. As an internal quality control for RNAi, squares
indicatepenetrance (50%[half-open]and0%[open])
of all associated visible RNAi phenotypes other than
aggregation. See also Figures S4A and S4B.
(B) Number of aggregates measured in Q40
and Q40;moag-2/lir-3(pk2183) worms upon RNAi
knockdown of tRNA-processing enzymes. See also
Figure S4C.
(C and D) Boxplot showing the relative expression
of different gene biotypes in Q40 and Q40;moag-
2/lir-3(pk2183) worms (C) and in N2 and Q40
wild-type worms (Q40 wild-type outcrossed from
pk2183) (D). TPM, tags per kilobase million; Coding,
protein-coding genes; ncRNA, non-coding RNA;
Pseudo, pseudogenes; snRNA, small nuclear RNA;
snlRNA, snRNA-like RNA; snoRNA, small nucleolar
RNA; tRNA, transfer RNA. See also Figures S4D
and S4E.
In (A) and (B), aggregate counting was performed at
the L4 stage and the average of three biological
replicates is represented. Data are represented as
mean ± SEM. In (C) and (D), the average of three
biological replicates is represented and signifi-
cance was calculated using a two-tailed unpaired
Student’s t test. ***p < 0.001; ns is not significant.
See also Figures S4D and S4E.worms (p < 0.001; Figures 4D and S4E). These findings explained
why mutations in moag-2/lir-3 could no longer reduce expres-
sion in these Q40 worms (Figures 4C and S4D) and indicated
that presence of polyglutamine results in downregulation of
small ncRNA expression.
MOAG-2/LIR-3 Increases Polyglutamine Toxicity
Having identified MOAG-2/LIR-3 as a regulator of polyglutamine
aggregation, we asked whether it regulates the toxicity of poly-
glutamine as well. To answer to this question, we compared
the motilities of worms with or without overexpression of FLAG-
tagged MOAG-2/LIR-3 in absence or presence of polyglutamine
over the course of 12 days. In absence of polyglutamine, FLAG-
tagged MOAG-2/LIR-3 had no effect on the motility of young
adults but improved themotility of old adult animals (Figure 5A). In
contrast, in worms expressing polyglutamine, overexpression of
MOAG-2/LIR-3 accelerated the age-dependent decline in
motility (Figure 5B). To note, a deletion in moag-2/lir-3 had
no significant effect on the motility of polyglutamine worms up
to 13 days of adulthood (Figure S5A). Our results with the
MOAG-2/LIR-3-overexpressing worms imply that the effect of a
deletion may not have been strong enough to be detected in
our assays because they indicate that increasing the levels of
MOAG-2/LIR-3 enhances the toxicity of polyglutamine.
MOAG-2/LIR-3 Can Directly Drive Polyglutamine
Aggregation
Our results indicate that MOAG-2/LIR-3 regulates protein
aggregation independently of its role in small ncRNA transcrip-1102 Molecular Cell 65, 1096–1108, March 16, 2017tion and processing. A possible mechanism by which loss of
MOAG-2/LIR-3 could suppress aggregation indirectly could be
by increasing the cellular folding capacity. The transcription of
protein-coding genes was not affected, however, indicating
that increased transcription of folding genes was not involved
(Table S3). Alternatively, MOAG-2/LIR-3may normally sequester
folding factors, which then may be released in the Q40;moag-2/
lir-3 mutants, a mechanism that has been previously proposed
for an increase in protein aggregation by temperature-sensitive
mutant proteins (Gidalevitz et al., 2006). If such a mechanism
would be responsible for the suppression of aggregation in the
Q40;moag-2/lir-3mutants, knockdown of folding factors in these
animals would increase aggregation again. To test this possibil-
ity, we knocked down by RNAi several folding factors that have
been previously shown to regulate polyglutamine aggregation
(Hsu et al., 2003; Nillegoda et al., 2015; Nollen et al., 2004; Ram-
pelt et al., 2012). The depletion of these factors could not revert
the aggregation phenotype in theQ40;moag-2/lir-3mutants (Fig-
ure S5B). These results suggest that suppression of protein ag-
gregation by inactivation of MOAG-2/LIR-3 is not caused by an
increase in the expression or a release of folding factors.
Another possibility is that MOAG-2/LIR-3 drives aggregation
directly. Precedents for aggregation-promoting factors include
MOAG-4/SERF, which can drive aggregation of a variety of
disease proteins via a transient direct interaction with early ag-
gregation intermediates (Davranche et al., 2011; Falsone et al.,
2012; Sittler et al., 1998; van Ham et al., 2010). To determine
whether MOAG-2/LIR-3 can drive aggregation directly, we incu-
bated GST-tagged huntingtin exon 1 containing 48 CAG repeats
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Figure 5. Polyglutamine Moves MOAG-2/LIR-3 Cytosol Where It Turns into a Positive Regulator of Protein Aggregation
(A and B) Number of body bends in N2 wild-type worms and worms overexpressing MOAG-2/LIR-3 (OE) (A) and Q40 wild-type and Q40 worms overexpressing
MOAG-2/LIR-3 (Q40;OE) (B). The average of three biological replicates is represented. Data are represented as mean ± SEM and significance was calculated
using a two-tailed unpaired Student’s t test. **p < 0.01; ***p < 0.001. See also Figure S5A.
(C) Thioflavin T reaction profiles of 4 mM HttQ48 or HttQ23 solutions in the absence or presence of equimolar concentrations of MOAG-2/LIR-3 (black) or the
modifier of aggregation MOAG-4 (blue). The concentration of MOAG-2/LIR-3 in whole-organism lysates has been determined to be between 0.3 and 8.5 ppm
(http://pax-db.org). The average of four replicates is represented and error bars indicate mean ± SD.
(D) Western blot of subcellular fractionation of MOAG-3/LIR-3, which was detected using a-FLAG antibody. Q40-YFP, LMN-1 (nuclear marker), and a-tubulin
(cytosolic marker) were used as controls. See Figure S5C.
(E) Western blot analysis of MOAG-2/LIR-3 SDS solubility from wild-type (WT) and MOAG-2/LIR-3-overexpressing (OE) worms in N2 and polyglutamine worms
(Q40). Q40-YFP and b-actin expression were included as controls.
In (D) and (E), the results were generated from L4-stage animals and a representative experiment of three biological replicates is shown.
(F) Model proposing how MOAG-2/LIR-3 drives polyglutamine aggregation. MOAG-2/LIR-3 normally regulates the transcription of small ncRNAs in the nucleus.
In the presence of polyglutamine, MOAG-2/LIR-3 is moved to the cytosol, where it exposes an ectopic aggregation-promoting activity.
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(HttQ48) with purified MOAG-2/LIR-3 protein and monitored
amyloid formation by measuring thioflavin T (ThT) fluorescence
in vitro. Our kinetic data revealed that the presence of an equi-
molar concentration of MOAG-2/LIR-3 accelerated the aggrega-
tion of HttQ48, but not of the non-pathogenic form HttQ23,
similarly to what was observed in the case of MOAG-4, the
C. elegansortholog of SERF1A (Figure 5C). These results indicate
that MOAG-2/LIR-3 can catalyze the deposition of aggregation-
prone proteins directly.
Polyglutamine Mislocalizes MOAG-2/LIR-3 from the
Nucleus to the Cytosol
For a lack of an aggregation-catalyzing effect to explain the
reduction of protein aggregation in Q40;moag-2/lir-3 mutants,
MOAG-2/LIR-3 and polyglutamine would, in the wild-type ani-
mals, have to localize in the same cellular compartment. Thus,
to determine their localization, we performed subcellular frac-
tionations with wild-type and Q40 worms with or without the
expression of FLAG-tagged MOAG-2/LIR-3. We found that in
the absence of polyglutamine, MOAG-2/LIR-3::FLAG was pri-
marily located in the nucleus (Figure 5D, OE; Figure S5C).
Polyglutamine was mostly localized in the cytosol, which was
independent of the presence of MOAG-2/LIR-3::FLAG (Fig-
ure 5D, Q40 and Q40;OE; Figure S5C). In Q40 worms, however,
MOAG-2/LIR-3::FLAG was enriched in the cytosol (Figure 5D,
OE and Q40;OE; Figure S5C), which suggests that the presence
of polyglutamine altered the localization of MOAG-2/LIR-3.
Their joint presence in the cytosol supports a direct interaction
between the proteins to drive protein aggregation.
Proteins involved in RNA metabolism have been described
to co-aggregate with polyglutamine (Doi et al., 2010; 2008;
Schwab et al., 2008), which could explain the retention of
MOAG-2/LIR-3 in the cytosol. We therefore fractionated SDS-
soluble and insoluble material to determine whether MOAG-2/
LIR-3 co-aggregated with polyglutamine. Q40-YFP was de-
tected as lowmolecular weight monomers and as SDS-resistant
species retained in the stacking gel (Figure 5D). The solubility of
MOAG-2/LIR-3::FLAG was not altered in the presence of poly-
glutamine (Figure 5D), suggesting that MOAG-2/LIR-3 is not re-
cruited to SDS-resistant aggregates, but may be associated
with the soluble species.
Together, these data suggest that the presence of polyglut-
amine moves MOAG-2/LIR-3 from the nucleus to the cytosol,
where it turns into a positive regulator of protein aggregation,
which is at the expense of its function as a transcriptional regu-
lator (Figure 5F).
DISCUSSION
From a genetic screen in a C. elegansmodel of protein aggrega-
tion disease, we identified MOAG-2/LIR-3 as a regulator of Pol III
transcription in the nucleus and showed that—in the presence of
polyglutamine—this protein switches into a positive regulator of
polyglutamine aggregation in the cytosol.
Our finding that MOAG-2/LIR-3 is a regulator of transcription
confirms predictions about the function of the lir-3 gene. Its
role as a transcriptional regulator has been suggested on the ba-
sis of its structural similarity to the C2H2 zinc fingers of LIN-26, a1104 Molecular Cell 65, 1096–1108, March 16, 2017fate regulator responsible for the differentiation of non-neuronal
ectodermal cells and somatic gonad epithelium (den Boer et al.,
1998; Dufourcq et al., 1999; Labouesse et al., 1996). We showed
that MOAG-2/LIR-3 is required for the transcription of snRNA,
snoRNA, and tRNA genes. In addition, we also showed that un-
like other transcription factors that have on occasion been found
to bind to the promoters of small ncRNAs, MOAG-2/LIR-3 is
associated with the same target genes as the Pol III complex
(Niu et al., 2011).
MOAG-2/LIR-3 is known to be expressed in the nuclei of a
subset of cell types ofC. elegans, namely bodywall muscle cells,
the vulval muscles, the spermatheca, the head and tail ganglia,
and the ventral nerve cord, from embryogenesis throughout
adulthood (https://transgeneome.mpi-cbg.de/transgeneomics/
index.html, March 2014; Reece-Hoyes et al., 2005, 2007). A mi-
croarray performed in two distinct mechanosensory neurons—
the touch receptor neurons and the FLP neurons—revealed
that moag-2/lir-3 is upregulated in the FLP sensory neurons,
suggesting that moag-2/lir-3 is required for FLP differentia-
tion (Topalidou and Chalfie, 2011). The observation that the
expression of MOAG-2/LIR-3 is limited to a subset of cell types
suggests that this protein could be a tissue-specific regulator
of transcription rather than a core component of the Pol III ma-
chinery. Such cell-type-specific regulators of Pol III have been
described for human cells and proposed to accommodate cell-
specific needs for small ncRNAs (Alla and Cairns, 2014; Oler
et al., 2010; also reviewed in Marshall and White, 2008; White,
2011). Whether MOAG-2/LIR-3 has a similar role remains to be
established, but it could explain why mutations in the moag-2/
lir-3 gene do not result in any obvious abnormalities in terms of
growth or viability.
In C. elegans, the nuclear pore protein NPP-13 has been
described to associate with the Pol III complex, which regulates
the efficient processing of snoRNAand tRNA transcripts (Ikegami
and Lieb, 2013). Knockdown of NPP-13 results in abnormally
long snoRNA and tRNA transcripts that cannot be processed
into their mature form (Ikegami and Lieb, 2013). In moag-2/lir-3
mutant worms, we did not find unprocessed transcripts for
snoRNA or for tRNAs (data not shown), which excludes the
possibility that MOAG-2/LIR-3 is required for Pol III transcript
processing. Moreover, knockdown of NPP-13 did not alter ag-
gregation, which suggests that mutations inmoag-2/lir-3 do not
alter aggregation by interfering with the nuclear pore complex.
Polyglutamine proteins can undergo post-translational modifi-
cations, including acetylation, phosphorylation, ubiquitation, and
sumoylation (reviewed in Ehrnhoefer et al., 2011; Pennuto et al.,
2009). These post-translational modifications have been shown
to modulate polyglutamine toxicity and aggregation (Gu et al.,
2009; Jana et al., 2005; Matsumoto et al., 2004; Steffan et al.,
2004; Thomas et al., 2004). One possibility that could explain
the reduction of aggregation observed in the polyglutamine
model is that mutations in moag-2/lir-3 alter the post-transla-
tional status of polyglutamine. Although with our present re-
sults we cannot exclude this possibility, our in vitro data
(Figure 5C) show that MOAG-2/LIR-3 is able to drive polyglut-
amine aggregation directly in conditionswhere post-translational
modifications do not occur, supporting a functional interaction
between MOAG-2/LIR-3 and polyglutamine.
In this study, expression of polyglutamine downregulated the
levels of snRNAs, snoRNAs, and tRNAs, demonstrating that ag-
gregation-prone proteins can affect small ncRNA homeostasis.
A possible explanation for this downregulation is that the aggre-
gation-prone proteins blocked the nuclear localization ofMOAG-
2/LIR-3 and perhaps also components of the Pol III complex.
Indeed, our data suggest that polyglutamine retains MOAG-2/
LIR-3 in the cytosol, which is consistent with the recent finding
that aggregation-prone proteins block trafficking in and out
of the nucleus (Woerner et al., 2016). Several intrinsically
disordered proteins—which include proteins involved in tran-
scriptional regulation—are known to be sequestered by aggre-
gation-prone proteins (Iakoucheva et al., 2002; Liu et al., 2006;
Minezaki et al., 2006; Olzscha et al., 2011; Walther et al.,
2015). One example is Sp1, which can no longer bind to its
DNA targets due to sequestration by mutant huntingtin (Dunah
et al., 2002; Li et al., 2002). We found that MOAG-2/LIR-3 is
not sequestered in the polyglutamine aggregates. The concen-
tration of MOAG-2/LIR-3 in whole-worm lysates has been deter-
mined to be between 0.3 and 8.5 ppm (http://pax-db.org).
Although these concentrations do not take into account cell-
or stage-specific differences in protein expression, its rela-
tively low abundance would support a model in which MOAG-
2/LIR-3 drives aggregation via transient interactions with rare
SDS-soluble polyglutamine species.
In summary, this work has revealed that protein aggregation
can affect the transcription of the non-coding genome by
altering the expression of ncRNA genes. Our findings also
open up another potential perspective on how aggregation-
prone proteins can impair cellular homeostasis: these proteins
can convert from their normal functions into aggregation-pro-
moting factors by relocation. These results imply a cellular
mechanism whereby aggregation-prone disease-associated
proteins inactivate, recruit, and use endogenous proteins that
promote their own aggregation and toxicity, which would
resemble viral self-catalysis of pathogenesis. We anticipate
that interfering with this class of gene products that promote
aggregation-prone interactions can be explored for the devel-
opment of therapies to slow down progression of age-related
protein aggregation diseases.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
C. elegans
The strains used in this study are listed in Table S1. Standardmethodswere used for culturingC. elegans at 20C (Brenner, 1974). The
LIR-3 overexpression strain (OP312) was generated by biolistic transformation to produce an integrated, low-copy transgene of the
WRM0637aB05 fosmid, recombined with GFP::3xFLAG in frame at the carboxy terminus of the lir-3 locus (Sarov et al., 2012). To
synchronize animals, eggswere collected from gravid hermaphrodites by hypochlorite bleaching and hatched overnight inM9 buffer.
The desired numbers of L1 animals were subsequently cultured on nematode growth medium (NGM) agar plates seeded with OP50
bacteria.
METHOD DETAILS
EMS mutagenesis and mapping
Mutagenesis was performed using standard C. elegans ethyl methanesulfonate (EMS) methodology (Jorgensen and Mango, 2002).
8000 mutagenized genomes were screened for suppressors of aggregation. moag-2(pk2183) was identified by single-nucleotide
polymorphismmapping to a region between base 9,400,743 and 11,827,697 on linkage group II (Wicks et al., 2001). Next generation
sequencing was performed in that region to identify candidate genes formoag-2. CLC Bio and MAQGene software were utilized for
mapping the mutation in F37H8.1 (listed in Key Resources Table).e2 Molecular Cell 65, 1096–1108.e1–e6, March 16, 2017
RNA interference
RNAi experiments were performed on NGM agar plates containing 1 mM IPTG and 50 mg/ml ampicillin and seeded with RNAi bac-
teria induced with IPTG to produce dsRNA. Worms were synchronized by hypochlorite bleaching; L1 worms were grown on RNAi
plates and used for the experiments at L4 stage, unless stated otherwise. Plates were coded so that the experimenter was blind
to the genotype of the animal.
Motility assay
At day 1, 4, 8 and 12 of adulthood, animals were placed in a drop ofM9 andwere allowed to recover for 30 s after which the number of
body bends was counted for 30 s. Fifteen animals were counted per experiment and the data from three biological replicates was
combined. Plates were coded so that the experimenter was blind to the genotype of the animal. The experiments with the N2 worms
and the Q40 animals were performed independently due to growth differences between the strains. In our laboratory conditions,
N2 worms take approximately 72 hr to reach L4 stage after hypochlorite treatment, whereas Q40 take approximately 96 hr.
Generation of transgenic strains
For the rescue experiment, a genomic construct of lir-3 spanning 1500 bp upstream to 330 bp downstream of F37H8.1 was amplified
from N2 genomic DNA by nested PCR using primers F1; R1; F2 and R2 (primer sequences listed in the Key Resources Table). The
resulting PCR fragment was cloned into the pGEM-T Easy Vector (#A1380, Promega) and sequenced. Transgenic linesweremade by
injecting 20 ng/ml of construct along with 10 ng/ml of pPD136.61 [P(unc-54::CFP)] into N2 animals. Two independent lines were
obtained for each transgene of interest.
Quantitative PCR
Total RNA was extracted from synchronized populations in L4 stage using Trizol (#15596-018, Life Technologies) according to the
manufacturer’s description. Total RNA quality and concentration were assessed using a NanoDrop 2000 spectrophotometer
(Thermo Scientific). cDNA was made from 2 mg total C. elegans RNA with a RevertAid H Minus First Strand cDNA Synthesis kit
(#K1632, Life Technologies) using random hexamer primers. Quantitative real-time PCR was performed using a Roche LightCycler
480 Instrument II (Roche Diagnostics) with SYBR green dye (#172-5125, Bio-Rad) to detect DNA amplification. The following cycle
conditions were used: 50C for 10 min, 95C for 10 min, followed by 40 cycles at 95C for 15 s and 57C for 30 s. Relative transcript
levels were quantitated using a standard curve of pooled cDNA solutions. Expression levels were normalized against the endogenous
reference gene cdc-42. The following primers were used: cdc-42_F3; cdc-42_R3; lir-3_F4 and lir-3_R4 (primer sequences listed in
the Key Resources Table).
To measure the efficiency of Pol III knockdown by RNAi, total RNA from 20 L4 animals was extracted using Trizol (Life Technolo-
gies). As a quality control step, total RNAwasmeasured using Qubit RNA HS Assay Kit (#Q32852, Thermo Fisher). Following DNase I
digestion (#EN0521, Fermentas), total RNA was purified with Trizol (Life Technologies). First strand synthesis was carried out using
Superscript II (Invitrogen) using random hexamer primers. Expression levels were normalized to the expression of rps-21 following
the 2DDCT method (Livak and Schmittgen, 2001). The primers used were rpc-1_F1; rpc1_R1; rps-21_F1 and rps-21_R1 (primer se-
quences listed in the Key Resources Table).
Chromatin immunoprecipitation sequencing
ChIP assays were conducted as previously described (Niu et al., 2011; Zhong et al., 2010). Worm staging was achieved by bleaching
and L1 starvation. Arrested L1 worms were plated on peptone-enriched NGM plates seeded with OP50 bacteria and grown for 48 hr
for L4 collection at 20C. Samples were cross-linked with 2% formaldehyde for 30 min at room temperature and then quenched with
1 M Tris pH 7.5. The pelleted worms were subsequently flash frozen in liquid nitrogen and stored at80C. Samples were sonicated
using a microtip to obtain DNA fragments mostly 200 to 800 bp in length. For each sample, 2.2 or 4.4 mg of cell extract was immu-
noprecipitated using a goat a-GFP antibody, GoatV (gift from Kevin White).
For library preparation and sequencing we used the enriched DNA fragments and input control (genomic DNA from the same sam-
ple) for two biological replicates as previously described (Kasper et al., 2014). Briefly, samples were multiplexed using the Ovation
Ultralow DR Multiplex Systems 1-8 and 9-16 (NuGEN Technologies) following the manufacturer’s protocol, with the exception that
QIAGEN MinElute PCR purification kits were used to isolate the DNA. Library size selection in the 200-800 bp range was achieved
using the SPRIselect reagent kit (Beckman Coulter) and sequencing was performed on the Illumina HiSeq 2000 platform. To search
for MOAG-2/LIR-3-specific binding sites, we only considered binding sites consistent across both replicates and within a range of
400 bp to +100 bp relative to the TSS. In addition, to avoid false positives in our analysis we excluded highly occupied target regions
(Gerstein et al., 2010). The ChIP seq data used was obtained from modENCODE DCC (http://www.modencode.org, September
2014). All ChIP seq data were deposited in the ENCODE database, under ID code ENCSR408FDZ and in ArrayExpress, under acces-
sion number E-MTAB-4174.
RNA sequencing
Wormswere grown to L4 stage and total RNAwas extracted using Trizol (Life Technologies) according to themanufacturer’s descrip-
tion. For polyA RNA sequencing, the TruSeq Sample Preparation V2 Kit was used (Illumina). For RNA sequencing (mRNA, snoRNA,Molecular Cell 65, 1096–1108.e1–e6, March 16, 2017 e3
tRNA and large ncRNA), a protocol has been described previously (Ikegami and Lieb, 2013). Briefly, total RNA was treated with
DNaseI and depleted from rRNA with the Ribominus Eukaryote Kit (#A10837-08, Invitrogen). Fragmentation of RNA was performed
using Fragmentation Buffer (#AM8740, Ambion) and cDNA was generated using the Superscript II Kit (Invitrogen). cDNA libraries
were subjected to high-throughput single-end sequencing (50 bp) in an Illumina HiSeq 2500 instrument. RNA sequencing data
was mapped to the WS220 genome reference using the TopHat 2.0.9 program (Kim et al., 2013) and gene annotation was derived
from Ensembl release 66. All RNA sequencing has been submitted to ArrayExpress, under accession number E-MTAB-4172.
Immunofluorescence
Indirect immunofluorescence was performed using the ‘‘freeze-cracking’’ method (Duerr, 2006). Briefly, synchronized worms at
L4 stage were fixed in 4% paraformaldehyde in 100 mM sodium phosphate buffer for 1 hr. Samples were washed three times
with TBS-T for 10 min and blocked in 10% goat serum in antibody buffer (PBS, 0.5% Triton X-100, 1mM EDTA, 0.1% BSA,
0.05% sodium azide, pH 7.2) for 1 hr. Anti-FLAG primary antibody (#F3165, Sigma-Aldrich) was applied at a 1:100 dilution overnight
at 4C. The next day, samples werewashed three times in antibody buffer for 20min and incubatedwith the secondary antibody Cy5-
labeled goat anti-mouse IgG (#A10524, Thermo Fisher) at a 1:500 dilution for 4 hr at room temperature. After washing with antibody
buffer three times, samples weremounted in Vectashieldmountingmediumwith DAPI (#H-1200, Vector Labs) and analyzed on a TCS
SP8 laser scanning confocal microscope with a 40x/1.30 NA objective lens (Leica).
Filter retardation assay
The protocol was adapted from Wanker et al. (Scherzinger et al., 1997; Wanker et al., 1999). Briefly, crude worm lysates from syn-
chronized L4 animals were resuspended in FTA sample buffer (10mMTris-Cl pH 8.0, 150mMNaCl, 2%SDS) with protease inhibitors
(Complete, Roche) and disrupted using a bead beater (FastPrep 24, MP Biomedicals) for 7 cycles of 20 s with 5 min rest in between
cycles. Supernatants were transferred to new 1.5 mL tubes, and protein concentration was determined. To detect SDS-insoluble
aggregates, 100 mg of total protein was mixed with 1 M DTT and FTA sample buffer (final concentration 40 mg/100 ml) and heated
at 98C for 5 min. Samples were filtered through a 0.22 micron cellulose acetate membrane using a 48-well Bio-Dot microfiltration
system (Bio-Rad) and 100 mg of total protein was used for the assay plus two five-fold serial dilutions. Proteins were blocked for
30 min with 5% milk in TBS-T. Membranes were incubated with the primary antibodies a-GFP (#632381, Clontech Laboratories)
or a-tubulin (#T6074, Sigma-Aldrich) at a 1:5000 dilution overnight at 4C. Incubation with the secondary a-mouse antibody was
at a 1:10 000 dilution for 1 hr at room temperature. Antibody binding was visualized with an ECL kit (#RPN2232, Amersham).
Co-immunoprecipitation
The protocol was adapted from (Ikegami et al., 2010). Briefly, crude worm lysates from synchronized L4 animals were resuspended in
FA buffer (50 mMHEPES/KOH pH 7.5, 1 mMEDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 150mMNaCl) supplemented with
protease inhibitors (Complete, Roche) and 1% sodium lauroyl sarcosinate (sarkosyl). Samples were cross-linked with formaldehyde
for 30 min and 2.5 M glycine for 5 min. Worms were disrupted using a bead beater (FastPrep 24, MP Biomedicals) for 7 cycles of 20 s
with 5 min rest in between cycles. Supernatants were transferred to new 1.5 mL tubes and protein concentration was determined.
Lysates were pre-cleared for 30 min with Protein G-Sepharose beads (Amersham) and incubated with primary antibodies a-Pol II
(#38520002, Novus Biologicals) or a-Pol III (#53330002, Novus Biologicals) at a dilution of 1:100 overnight at 4C. Lysates were
coupled to Protein G-Sepharose beads (Amersham) for 1 hr and washed five times for 5 min with FA buffer supplemented with
1 mM PMSF and protease inhibitor cocktail (Complete, Roche). Proteins were eluted by boiling the beads in SDS sample buffer
and analyzed by western blotting.
Protein insolubility assay
Synchronized worms at L4 stage animals were resuspended in FA buffer and disrupted using a bead beater (FastPrep 24, MP Bio-
medicals) for 7 cycles of 20 s with 5 min rest in between cycles, followed by 15 sonication steps of 30 s with 30 s rest between cycles.
Protein concentration was determined and equal amounts of lysates were incubated with 2% SDS for 1 hr at room temperature. The
lysates were centrifuged at 13 300 rpm for 30 min and the supernatant (soluble fraction) was collected. The pellet (insoluble fraction)
was washed two times with FA buffer and resuspended in urea buffer (8M urea, 2% SDS, 50 mM DTT, 50 mM Tris pH 8) for 1 hr. The
samples were subsequently analyzed by western blotting.
Protein purification
Recombinant moag-2/lir-3 was expressed and purified fused to the glutathione S-transferase (GST) from the pGEX-6-P1 vector in
E. coli BL21 (DE) gold strain (Stratagene). Cells were grown in Overnight Express Instant TBMedium (Merck Millipore) supplemented
with ampicillin (100 mg/ml) overnight at 30C under constant shaking at 250 rpm. The cells were harvested by centrifugation, resus-
pended in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA and EDTA-Free protease inhibitor cocktail (Complete, Roche)
and lysed by sonication. The cell debris was removed by centrifugation at 18 000 rpm (JA-25.50 rotor, Beckman Coulter). The su-
pernatant was loaded onto a column containing Glutathione Sepharose 4 Fast Flow resin (GE Healthcare LifeSciences) and equili-
brated with lysis buffer. The column was washed with 40 CV of lysis buffer and the protein was eluted in 50 mM Tris pH 8, 10 mM
reduced glutathione and dialyzed in 50 mM Tris pH 7.4, 150 mM NaCl for the aggregation experiments.e4 Molecular Cell 65, 1096–1108.e1–e6, March 16, 2017
Aggregation kinetics
4 mM solutions of GST-HttQ48 or GST-HttQ23 alone or with an equimolar concentration ofmoag-2/lir-3 ormoag-4were incubated in
the presence of 7U of PreScission protease (GE Healthcare LifeSciences) per nmol of Htt protein in 50mM Tris pH 7.4, 150mMNaCl,
20 mM Thioflavin T at 37C. The aggregation reactions were performed under constant linear shaking at 500 rpm and the ThT fluo-
rescence was monitored in low-binding, clear-bottomed half-area 96-well plates. Emissions at 480 nm were recorded every 300 s
with excitation at 440 nm, using a CLARIOstar plate reader (BMG Labtech). Fluorescence values were analyzed with the following
sigmoidal equation:
y =A0+
A A0
1+ expð  ðt  t50%Þ  KaggÞ;
where A0 and A are the values at the beginning and the end of the aggregation, mA0 and mA are the slopes of the lag phase and the
plateau, assuming for them a linear dependency of normalized fluorescence values with the incubation time, t50% is the midpoint of
aggregation and kagg is the apparent aggregation rate constant.
Subcellular fractionation
The protocol was adapted from (Chen et al., 2000). Briefly, crude worms lysates from synchronized L4 animals were resuspended in
hypotonic buffer (15 mM HEPES KOH pH 7.6, 10 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 350 mM Sucrose, 1 mM PMSF, 1 mM DTT,
supplemented with protease inhibitors cocktail (Complete, Roche). Animals were homogenized usingmicrotube pestle rods andmo-
tor (Kontes) by applying 10 strokes of 1min followed by 1min rest in between strokes.Worm debris was removed by centrifugation at
500 g for 5 min at 4C. The pellet was discarded and the supernatant was used as input of the cell fractionation. Nuclei were pelleted
at 4000 g for 5 min at 4C. The supernatant containing the cytosolic fraction was centrifuged at 17 000 g for 30 min at 4C to remove
membrane fraction and contaminants. The nuclear fraction was washed two times with hypotonic buffer and resuspended in hyper-
tonic buffer (15 mM HEPES KOH pH 7.6, 400 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.1% Tween 20, 10% Glycerol, 1 mM PMSF,
1 mM DTT, supplemented with protease inhibitors cocktail (Complete, Roche)). The nuclear fraction was homogenized using
29G ± inch needle insulin syringe (Terumo) and treated with 25 U/ml Benzonase (Millipore) for 30 min at 4C. Ten mg of each fraction
was loaded on a 12% SDS-PAGE. Gels were transferred to nitrocellulose membranes (Brunschwig Chemie) and incubated with the
primary antibodies a-FLAG (#F3165, Sigma-Aldrich) at a 1:1000 dilution; a-LMN-1 (#38530002, Novus Biologicals) at a 1:1000 dilu-
tion; a-GFP (#632381, Clontech Laboratories) and a-tubulin (#T6074-200UL, Sigma-Aldrich) at a 1:5000 dilution overnight at 4C.
Incubation with the secondary antibody was at a 1:10 000 dilution for 1 hr at room temperature. Antibody binding was visualized
with an ECL kit (#RPN2232, Amersham).
Bioinformatic analysis
Conserved domains were identified using SMART (Simple Modular Architecture Research Tool) (Letunic et al., 2012; Schultz et al.,
1998). Nuclear signal localization was predicted using NLS Mapper (Kosugi et al., 2009). Protein folding was predicted using
FoldIndex (Prilusky et al., 2005). The algorithm used for motif discovery was the MEME Suite (Bailey et al., 2009). Orthologs were
identified using protein BLAST search (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and aligned with T-Coffee multiple sequence align-
ment tool (Notredame et al., 2000). Amino acid predictions were performed using ORF Finder (https://www.ncbi.nlm.nih.gov/gorf/
orfig.cgi).
QUANTIFICATION AND STATISTICAL ANALYSES
Quantification of aggregates and motility assay
The number of aggregates present in whole worms was counted using a fluorescence dissection microscope (Leica). A minimum of
20 worms was counted and the data from three or four biological replicates were combined. For the motility assay, 15 animals were
counted per experiment and the data from three biological replicates was combined.
A biological replicate was defined as an independently grown worm population, before extraction of embryos from gravid adult
hermaphrodites to obtain synchronized populations (see Experimental Model and Subject Details). The exact number of biological
replicates is indicated in the figure legends. Data are represented as mean ± SEM and significance was calculated using a one-tailed
or two-tailed unpaired Student’s t test. The exact type of Student’s t test is indicated in the figure legend. *p < 0.05 **p < 0.01;
***p < 0.001.
RNA sequencing data analysis
All RNA seq are represented as the mean of n = 3 biological replicates, with error bars representing mean ± SEM. A generalized linear
model was used to identify differential gene expression between the Q40wild-type and the Q40mutants with EdgeR (Robinson et al.,
2010; McCarthy et al., 2012). Replicates 1-3 were introduced as a technical factor to correct for batch effect. Genes with average
expression level below 1 fragment per million (FPM) were excluded from the analysis. The library normalization was left at theMolecular Cell 65, 1096–1108.e1–e6, March 16, 2017 e5
standard setting (trimmed mean of M-values, TMM). The resulting p values were corrected for multiple testing using the Benjamini-
Hochberg procedure. Per gene expression data was normalized as FPM. Data visualization and statistical tests were conducted
using R scripts (available upon request).
Quantitative PCR analysis
All quantitative PCR are represented as themean of n = 3 biological replicates, with error bars representingmean ± SEM. Tomeasure
the relative lir-3 mRNA expression, lir-3 transcript levels were quantitated using a standard curve of pooled cDNA solutions and
expression levels were normalized against the endogenous reference gene cdc-42. To measure the relative Pol II or Pol III mRNA
expression, the corresponding transcript levels were normalized to the expression of rps-21 following the 2-DDCT method (Livak
and Schmittgen, 2001) (see Method Details).
Filter retardation assay
Immunoblots were quantified by densitometry using ImageJ (listed in Key Resources Table). To quantify the relative amount of SDS-
insoluble protein, a ratio (fold change) was calculated by dividing the values of Q40;moag-2/lir-3mutants by their corresponding wild-
types (corrected to a-tubulin as a loading control).
DATA AND SOFTWARE AVAILABILITY
The accession numbers for the ChIP-seq data reported in this paper are ENCODE: ENCSR408FDZ and ArrayExpress:
E-MTAB-4174. The accession number for the RNA-seq data reported in this paper is ArrayExpress: E-MTAB-4172. Full images
used in this study have been deposited to Mendeley Data and are available at http://dx.doi.org/10.17632/knzkvgbf6x.2.e6 Molecular Cell 65, 1096–1108.e1–e6, March 16, 2017
